NEUROPSYCHOPHYSIOLOGICAL EVALUATION OF THREE DOSES OF S 12024-2 IN MILD-TO-MODERATE ALZHEIMER'S DISEASE

This study was designed to obtain early evidence that S 12024-2 has potential central pharmacological activity and cognition-enhancing properties in patients with Alzheimer’s disease (AD). This was a single centre, double-blind, crossover study employing three oral doses of S 12024-2 (50, 100, 200mg once daily) and placebo administered over 7 days (Latin square design). 12 outpatients with mild AD (Mini-Mental State Examination scores 18 to 26) were selected according to the National Institute for Neurological and Communication Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association criteria. Clinical and electrophysiological assessments were used as follows: • Clinical assessment was performed using: (a) a semicomputerised battery assessing memory and attention (VDL); (b) the Clinician Interview-Based Impression of Change (CIBIC); (c) an Activities of Daily Living scale filled in by the caregiver • Electrophysiological assessment was performed using Quantitative EEG (qEEG) and Event Related Potentials (ERPs).